|
|
Rxsight Inc (NASDAQ: RXST) |
|
Price: $7.3300
$0.28 
3.972%
|
| Day's High:
| $7.360000133514404
| Week Perf:
| 14.53 %
|
| Day's Low: |
$ 7.00 |
30 Day Perf: |
21.96 % |
| Volume (M): |
1,289,517 |
52 Wk High: |
$ 13.22 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$7.86 |
| Open: |
$7.05 |
52 Wk Low: |
$4.48 |
|
|
| Market Capitalization (Millions $) |
303 |
| Shares
Outstanding (Millions) |
41 |
| Employees |
461 |
| Revenues (TTM) (Millions $) |
127 |
| Net Income (TTM) (Millions $) |
-47 |
| Cash Flow (TTM) (Millions $) |
-10 |
| Capital Exp. (TTM) (Millions $) |
4 |
Business Description
RxSight Inc. is a medical technology company that specializes in developing and manufacturing intraocular lens (IOL) systems for cataract patients. The company has developed an innovative IOL platform called the Light Adjustable Lens (LAL), which allows for postoperative adjustments to the lens power and corrects residual refractive errors. This technology helps patients achieve better visual outcomes after cataract surgery. RxSight Inc. was founded in 1998 and is headquartered in California, United States.
Company Address: 100 Columbia Aliso Viejo 92656 CA
Company Phone Number: 521-7830 Stock Exchange / Ticker: NASDAQ RXST
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Announcement
Published Fri, Sep 19 2025 1:24 AM UTC
Making Sense of Market Movements: Insights into RxSight s Recent Decline and What It Means for Shareholders In the intricate world of investment, keeping a vigilant eye on market shifts and company performances is paramount for shareholders striving to make informed decisions. As we venture deeper into the vibrant yet challenging landscape of the stock market, attention has ...
|
| Announcement
Published Mon, Sep 15 2025 11:36 AM UTC
In recent weeks, shareholders of RxSight, Inc. (NASDAQ: RXST) have found themselves in a complex financial landscape as news of a securities class action has been announced. The Rosen Law Firm, a globally recognized firm specializing in investor rights, has issued a reminder to investors regarding an important lead plaintiff deadline of September 22, 2025. This announcement ...
|
| Announcement
Published Mon, Sep 8 2025 10:39 AM UTC
Investors on Alert: Class Action Lawsuit Looms Over RxSight, Inc. The financial landscape can be perilous, and for investors of RxSight, Inc. (NASDAQ: RXST), those turbulent waters are presently more daunting. Pomerantz LLP, a firm renowned for protecting shareholder rights, has sounded an alarm for such investors. A class action lawsuit has been filed against RxSight, a com...
|
| Announcement
Published Wed, Jul 23 2025 3:45 PM UTC
Investor Concerns Prompt Pomerantz Law Firm Investigation into RxSight, Inc. In a recent announcement, Pomerantz LLP, a prominent law firm specializing in securities litigation, has launched an investigation into potential claims on behalf of investors in RxSight, Inc. (NASDAQ: RXST). This inquiry comes in response to concerns regarding the company s business practices and d...
|
| Financing Agreement
Published Mon, May 13 2024 8:05 PM UTC
RxSight, Inc. Enhances Tangible Leverage Ratio, Closing Successful Public Offering of Common Stock
Aliso Viejo, Calif. - May 13, 2024 - RxSight, Inc. (Nasdaq: RXST), a leading ophthalmic medical device company specializing in customized vision solutions for patients post-cataract surgery, has successfully closed its underwritten public offering of common stock. The offer...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-0.18 $ |
| Revenues (TTM) |
3.08 $
|
| Cash Flow (TTM) |
- |
| Cash |
5.27 $
|
| Book Value |
6.47 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
275,874 |
| Net
Income per Employee (TTM) |
-101,167 |
| Receivable Turnover Ratio (TTM) |
5.19 |
| Inventory Turnover Ratio (TTM) |
0.96 |
| Asset Turnover Ratio (TTM) |
0.42 |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.18 $
|
| Revenues (TTM) |
3.08 $ |
| Cash Flow (TTM) |
- |
| Cash |
5.27 $
|
| Book Value |
6.47 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| L D D |
|
 7.71 % |
of total Revenue |
| LAL |
|
88.65 % |
of total Revenue |
| Service Warranty Service Contracts And Accessories |
|
4.93 % |
of total Revenue |
| |
On February 25 2025 the Rxsight Inc provided following guidance
nnRxSight, Inc. Announces Financial Results for Q4 and Full-Year 2024, Confirms 2025 Projectionsnn
ALISO VIEJO, Calif., February 25, 2025 – RxSight, Inc., a pioneering company in ophthalmic medical devices committed to delivering premium tailored vision solutions for patients post-cataract surgery, has published its financial performance report for the fourth quarter and the entirety of 2024.
In this latest announcement, the company has reiterated its projections for the year 2025. Although specifics regarding the financial outlook were not disclosed in detail, the affirmation signals continued confidence in the firm's strategic direction and operational execution.
For the quarte...
|
|
|
0.92% 